We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

54 hedge funds and large institutions have $404M invested in ArriVent BioPharma in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

2% more funds holding

Funds holding: 53 → 54 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

4% more capital invested

Capital invested by funds: $389M → $404M (+$15.3M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3.71% less ownership

Funds ownership: 68.37% → 64.66% (-3.7%)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.78%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
12
Increased
23
Reduced
7
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
+$9.91M
2
NHAS
Novo Holdings A/S
Denmark
+$7.54M
3
SCM
Suvretta Capital Management
New York
+$2.66M
4
HLAM
Hidden Lake Asset Management
New York
+$662K
5
State Street
State Street
Massachusetts
+$559K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$5.12M
2
Millennium Management
Millennium Management
New York
-$3.56M
3
FCM
Farallon Capital Management
California
-$2.71M
4
OCA
Octagon Capital Advisors
New York
-$2.51M
5
MA
MYDA Advisors
New York
-$536K
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
51
Carson Wealth (CWM LLC)
Nebraska
$1K +$1.03K +58 New
Nisa Investment Advisors
52
Nisa Investment Advisors
Missouri
$501 +$481 +27 New
GI
53
GAMMA Investing
California
$186 +$178 +10 New
RIL
54
Rothschild Investment LLC
Illinois
$93 +$89 +5 New
ACP
55
Altitude Crest Partners
Connecticut
– -$9.92M -555,555 Closed
Citadel Advisors
56
Citadel Advisors
Florida
– -$5.12M -286,512 Closed
FCM
57
Farallon Capital Management
California
– -$2.71M -151,768 Closed
MA
58
MYDA Advisors
New York
– -$536K -30,000 Closed
Point72 Asset Management
59
Point72 Asset Management
Connecticut
– -$516K -28,900 Closed
UOC
60
UBS O'Connor
Illinois
– -$468K -26,181 Closed
Blackstone Inc
61
Blackstone Inc
New York
– -$447K -25,000 Closed
PD
62
Point72 (DIFC)
United Arab Emirates
– -$391K -21,890 Closed
AIG
63
American International Group
New York
– -$86.5K -4,845 Closed
CSS
64
Cubist Systematic Strategies
Connecticut
– -$77.9K -4,360 Closed
MLICM
65
Metropolitan Life Insurance Company (MetLife)
New York
– -$10.1K -567 Closed
1 2
3

AVBP Hedge Fund Activity: Q2 2024 in Review

54 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2024, worth a combined $404M — up 3.9% from $389M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new AVBP positions and 11 closed out — a net gain of 1 holder — while 23 added to existing stakes and 7 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $9.91M. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.12M sold.

  • 54 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2024, up from 53 in Q1 2024.
  • Funds reported $404M of ArriVent BioPharma stock for Q2 2024, up 3.9% quarter-over-quarter.
  • 12 funds opened new ArriVent BioPharma positions in Q2 2024 and 11 closed out, a net change of +1 holder.
  • The largest ArriVent BioPharma buyer in Q2 2024 was HHLR Advisors, an estimated $9.91M added.
  • The largest ArriVent BioPharma seller in Q2 2024 was Citadel Advisors, an estimated $5.12M sold.

Based on aggregated 13F filings for Q2 2024.